ALBAYRAK, C. Et Al. 2021. Real-World Evidence from the Compassionate Use Programme of EHL rFVIIIFc fusion protein (efmoroctocog alfa) in the prophylaxis and treatment of bleeding in patients with haemophilia A. 18th International Hemophilia Congress of Turkey .

ALBAYRAK, C., AR, M. C., EYÜPOĞLU, S. A., CELKAN, T. T., KÜPESİZ, O. A., ŞAHİN, F., ... ŞAŞMAZ, H. İ.(2021). Real-World Evidence from the Compassionate Use Programme of EHL rFVIIIFc fusion protein (efmoroctocog alfa) in the prophylaxis and treatment of bleeding in patients with haemophilia A . 18th International Hemophilia Congress of Turkey

ALBAYRAK, CANAN Et Al. "Real-World Evidence from the Compassionate Use Programme of EHL rFVIIIFc fusion protein (efmoroctocog alfa) in the prophylaxis and treatment of bleeding in patients with haemophilia A," 18th International Hemophilia Congress of Turkey, 2021

ALBAYRAK, CANAN Et Al. "Real-World Evidence from the Compassionate Use Programme of EHL rFVIIIFc fusion protein (efmoroctocog alfa) in the prophylaxis and treatment of bleeding in patients with haemophilia A." 18th International Hemophilia Congress of Turkey , 2021

ALBAYRAK, C. Et Al. (2021) . "Real-World Evidence from the Compassionate Use Programme of EHL rFVIIIFc fusion protein (efmoroctocog alfa) in the prophylaxis and treatment of bleeding in patients with haemophilia A." 18th International Hemophilia Congress of Turkey .

@conferencepaper{conferencepaper, author={CANAN ALBAYRAK Et Al. }, title={Real-World Evidence from the Compassionate Use Programme of EHL rFVIIIFc fusion protein (efmoroctocog alfa) in the prophylaxis and treatment of bleeding in patients with haemophilia A}, congress name={18th International Hemophilia Congress of Turkey}, city={}, country={}, year={2021}}